

Review Article

Artificial Intelligence in Modern Healthcare: Advances in Drug Repurposing, Mental Health Monitoring and Clinical Decision Support Systems**Karthik Kumar Vaigandla^{1,*}**¹Associate Professor, Electronics and Communication Engineering, Balaji Institute of Technology and Science, Warangal, Telangana, India - 506331Corresponding Author: Karthik Kumar Vaigandla. Email: ykvaigandla@gmail.comReceived: 12/01/2026; Revised: 28/01/2026; Accepted: 26/02/2026; Published: 31/03/2026
<https://doi.org/10.69996/jsihs.2026001>

Abstract: The integration of computational intelligence in modern healthcare has ushered in transformative advancements across various domains, significantly enhancing diagnosis, treatment, and patient care. This review explores recent progress in three critical areas: drug repurposing, mental health monitoring, and clinical decision support systems. Drug repurposing leverages large-scale biological and chemical data to identify new therapeutic applications for existing medications, offering a faster and cost-effective pathway to treatment development. In the realm of mental health, digital tools combined with physiological and behavioral data are being used to detect early symptoms, monitor patient progress, and personalize therapeutic interventions. Furthermore, clinical decision support systems are playing a vital role in assisting healthcare professionals by synthesizing patient history, laboratory results, and medical guidelines to recommend accurate and timely interventions. These systems not only reduce diagnostic errors but also improve workflow efficiency and patient outcomes. The review critically examines key methodologies, practical implementations, and real-world applications, while also addressing ethical challenges, data privacy concerns, and regulatory considerations. By synthesizing current research and healthcare practices, this article aims to provide a comprehensive overview of how advanced computational techniques are reshaping the delivery of healthcare services.

Keywords: Artificial Intelligence, Healthcare, Clinical Decision, Drug Repurposing.

1. Introduction

The healthcare sector has long been a focal point for technological innovation, with continuous efforts directed toward improving patient care, optimizing resource use, and enhancing medical decision-making. In recent years, the increasing volume and complexity of medical data, coupled with the demand for precision and personalized care, have driven the adoption of advanced computational techniques in healthcare systems. These developments are not merely supplementary but are gradually becoming integral to the functioning of modern medical institutions [1]. Among the key areas benefiting from computational advances are drug repurposing, mental health monitoring, and clinical decision support systems. Each of these domains addresses crucial challenges in healthcare delivery, ranging from the high costs and extended timelines of drug development to the under diagnosis of mental health disorders and the persistent risk of diagnostic and treatment errors in clinical practice. Drug repurposing has emerged as a promising strategy for identifying new therapeutic uses for existing pharmaceutical compounds. This approach minimizes the time and cost associated with traditional drug discovery, which typically spans several years and requires extensive clinical validation. By analyzing chemical structures, biological pathways, and historical clinical outcomes, researchers



are now able to uncover previously unknown drug-disease relationships. The utility of this approach was particularly evident during public health emergencies such as the COVID-19 pandemic, where swift identification of effective treatments became a global priority [2]. In the realm of mental health, traditional diagnostic practices often rely on subjective assessments and self-reported symptoms, which can lead to misdiagnosis or delayed intervention. To address these limitations, modern monitoring tools now incorporate data from multiple sources, such as voice recordings, facial expressions, and wearable sensor data to offer more objective and continuous assessment of mental well-being. These tools not only support early detection but also enable ongoing monitoring of treatment efficacy, thus improving the long-term outcomes for individuals affected by mood disorders, anxiety, and other psychological conditions [3]. Clinical decision support systems are another vital component of modern healthcare transformation. These systems are designed to assist medical professionals by integrating patient-specific information with medical knowledge bases to generate evidence-based recommendations. Whether it's flagging potential drug interactions, suggesting diagnostic tests, or proposing treatment protocols, decision support systems contribute significantly to reducing human error and enhancing clinical efficiency. Their value is particularly pronounced in high-pressure environments such as emergency rooms and intensive care units, where timely and accurate decisions are critical [4]. This review article explores the recent developments, underlying methodologies, and practical implementations within these three focal areas. It also addresses the challenges related to data integration, privacy, interpretability, and regulatory compliance. By presenting a comprehensive analysis, the article aims to inform researchers, healthcare professionals, and policymakers about the transformative potential and limitations of computational methods in contemporary medical practice.

2. Introduction to Artificial Intelligence (AI)

Artificial Intelligence (AI) is a multidisciplinary branch of computer science aimed at creating systems capable of performing tasks that normally require human intelligence. It involves the simulation of cognitive functions such as reasoning, learning, problem-solving, perception, and language understanding by machines [5-7]. AI integrates concepts from computer science, mathematics, statistics, cognitive psychology, neuroscience, and linguistics. The concept of AI dates back to the 1950s, when pioneers like Alan Turing, John McCarthy, and Marvin Minsky explored the possibility of creating “thinking machines.” Over the decades, AI has evolved from simple rule-based systems to advanced learning algorithms capable of handling massive datasets and making complex decisions [8]. Modern AI systems are driven by vast computational power, large-scale data availability, and sophisticated algorithms such as deep learning. AI has become embedded in daily life, powering virtual assistants, recommendation systems, autonomous vehicles, fraud detection systems, and advanced medical diagnostics. AI is widely applied across diverse domains, bringing efficiency, accuracy, and scalability to complex tasks is described in Table 1.

2.1 Basic Operation of Artificial Intelligence

AI systems operate through a series of structured processes that allow machines to perceive inputs, process data, learn from experiences, and perform actions [9].

Data Collection and Input : AI relies heavily on high-quality and relevant data. Inputs may come from various sources such as sensors, cameras, databases, text files, audio signals, or user interactions. For instance, a facial recognition system uses images or video frames as its primary input.

Data Preprocessing: Raw data often contains noise, errors, and inconsistencies. Preprocessing involves cleaning the data, removing irrelevant elements, normalizing formats, and transforming it into a structure suitable for machine learning models. Techniques such as data scaling, feature extraction, and dimensionality reduction are often applied.

Model Selection: AI models are chosen based on the nature of the problem. Examples include:

- Supervised Learning Models (e.g., decision trees, neural networks, support vector machines) for classification and regression tasks.
- Unsupervised Learning Models (e.g., k-means clustering, principal component analysis) for pattern recognition without labeled data.
- Reinforcement Learning Models for decision-making in dynamic environments.

Training: The chosen AI model is trained using historical datasets. In supervised learning, the model learns patterns from labeled examples. In reinforcement learning, it improves through feedback from the environment in the form of rewards or penalties.

Inference and Prediction: Once trained, the AI system can make predictions or decisions based on new, unseen data. For example, a medical AI model trained on thousands of X-ray images can predict the likelihood of a patient having pneumonia.

Feedback and Optimization: Continuous feedback improves AI performance. Models may be retrained periodically to adapt to new patterns or changes in data distribution, ensuring their relevance and accuracy over time.

Table 1: Applications of AI [10]

Parameter	Description
Healthcare	• Medical imaging analysis for disease detection. • Predictive analytics for patient outcomes. • Drug discovery and personalized medicine. • Virtual health assistants for patient guidance.
Business and Finance	• Automated customer service through chatbots. • Fraud detection in banking and insurance. • Market trend prediction and algorithmic trading. • Supply chain optimization.
Transportation	• Self-driving vehicles using computer vision and sensor fusion. • Traffic management systems. • Predictive maintenance for vehicles and infrastructure.
Education	• Personalized learning platforms. • AI-powered grading systems. • Intelligent tutoring systems that adapt to student learning styles.
Manufacturing	• Robotics and automation for assembly lines. • Quality control through visual inspection. • Predictive maintenance to reduce downtime.
Agriculture	• AI-based crop monitoring and yield prediction. • Automated irrigation and pest control. • Climate impact forecasting.
Security and Defense	• Surveillance and threat detection. • Cybersecurity threat identification and prevention. • Autonomous drones for reconnaissance.

2.3 Future Trends in Artificial Intelligence

AI is rapidly evolving, with future developments expected to revolutionize multiple industries [11].

Explainable AI (XAI): Growing demand for transparent AI models that provide clear reasoning for their decisions to improve trust and accountability.

Edge AI: AI processing at the edge (on local devices) will reduce latency, improve privacy, and enable faster decision-making for IoT and mobile applications.

AI in Healthcare Breakthroughs: More advanced diagnostic systems capable of early detection of complex diseases, real-time health monitoring, and AI-assisted surgeries.

Generative AI: Increased use of AI models that can generate realistic images, videos, text, and music for creative industries.

Integration with 5G and 6G: High-speed networks will enable low-latency AI applications like autonomous transport, remote robotic surgeries, and immersive augmented reality.

AI for Sustainability: AI tools will optimize energy usage, monitor climate change impacts, and manage resources for sustainable development.

Human-AI Collaboration: Hybrid systems where AI assists humans in decision-making without fully replacing them, ensuring efficiency with ethical oversight.

2.4 Challenges in Artificial Intelligence

Despite its benefits, AI faces multiple challenges that limit its widespread adoption [12].

Data Privacy and Security: AI models often require massive amounts of personal data, raising concerns about data misuse, breaches, and unauthorized surveillance.

Bias and Fairness: AI can inherit biases from training data, leading to unfair decisions in hiring, lending, law enforcement, and healthcare.

Explainability: Complex AI models like deep neural networks often operate as “black boxes,” making it difficult to understand their reasoning.

High Computational Costs: Training large AI models demands significant computing power and energy, leading to high operational costs and environmental concerns.

Job Displacement: Automation powered by AI can replace certain human roles, raising concerns about unemployment and the need for workforce reskilling.

Regulatory and Ethical Issues: The lack of standardized regulations leads to uncertainty about the legal implications of AI decisions, especially in safety-critical systems.

Security Vulnerabilities: AI systems can be targeted by adversarial attacks, where small input manipulations cause incorrect outputs, potentially leading to dangerous outcomes.

3. AI in Drug Repurposing and Discovery

Drug discovery has traditionally been a lengthy, expensive, and uncertain process, often requiring over a decade of development and billions of dollars in investment. Even with such significant resources, the likelihood of success for a new drug to pass through clinical trials and reach the market remains relatively low. In this context, drug repurposing identifying new therapeutic applications for already approved or investigational drugs has gained prominence as a practical and efficient strategy. It allows for faster clinical translation, reduced risk of failure, and cost savings, as safety profiles and pharmacokinetics of these compounds are already well-documented. In recent years, advancements in data analysis techniques have played a pivotal role in accelerating both drug discovery and repurposing efforts, fundamentally altering how

researchers approach biomedical innovation [13-17].

3.1 Understanding Drug Repurposing

Drug repurposing, also known as drug repositioning, involves the investigation of existing drugs for new disease indications. Unlike conventional drug discovery that begins with target identification and high-throughput screening of thousands of new compounds, repurposing focuses on compounds that have already passed several stages of development, including preclinical studies and, often, clinical trials for other conditions. Examples of successful drug repurposing include sildenafil, originally developed for angina but later approved for erectile dysfunction, and thalidomide, repurposed for multiple myeloma treatment despite its controversial history [18]. Drug repurposing strategies generally fall into two categories: activity-based and knowledge-based. Activity-based approaches rely on laboratory experiments such as phenotypic screening, while knowledge-based approaches depend on computational techniques to analyze molecular, clinical, and pharmacological data. The latter has gained significant traction due to the growing availability of public databases, electronic health records, chemical structure libraries, gene expression datasets, and scientific literature.

3.2 Computational Techniques in Drug Repurposing

The foundation of modern drug repurposing lies in the ability to integrate and analyze diverse datasets. Several computational methods are employed to identify hidden patterns and potential drug-disease relationships [19].

Network-Based Approaches: Biological systems can be represented as networks comprising genes, proteins, metabolites, and diseases as nodes connected by various interactions. In these networks, drug repurposing can be performed by identifying drugs that target disease-related nodes or pathways. By constructing drug-target, gene-disease, and protein-protein interaction networks, researchers can discover new connections between existing drugs and unrelated disease conditions. These methods help in prioritizing candidate compounds for further validation.

Similarity-Based Methods: Drugs and diseases can be compared based on structural, functional, or phenotypic similarities. Compounds with similar chemical structures or side effect profiles may act on similar targets. Likewise, diseases that share molecular mechanisms or clinical symptoms may respond to the same treatment. These similarity metrics are used to cluster drugs and diseases and suggest possible therapeutic links.

Transcriptomic Signature Matching: A more advanced method involves matching gene expression profiles of drugs and diseases. In disease conditions, certain genes are overexpressed or suppressed. If a drug reverses the gene expression signature of a disease, it may have therapeutic potential. The Connectivity Map (CMap) is one such resource that enables researchers to compare drug-induced gene expression profiles with disease-associated profiles, facilitating the identification of candidate drugs that can counteract the disease process at the transcriptional level.

Molecular Docking Simulations: This technique involves modeling how a drug molecule physically binds to a biological target, such as a receptor or enzyme. By evaluating the strength and specificity of the interaction, docking simulations can identify potential new targets for existing drugs. This method is particularly useful in identifying off-target effects that may have therapeutic value.

Integration of Multi-Omics Data: Modern drug repurposing also leverages data from genomics, proteomics, metabolomics, and other omics technologies. By integrating these data

types, researchers can gain a comprehensive understanding of disease mechanisms and drug actions. For example, combining genomic mutations, protein expression patterns, and metabolic changes provides a holistic view of how a disease progresses and how a drug might intervene.

3.3 Applications and Case Studies

Several recent efforts have demonstrated the success of these techniques in repurposing drugs for various diseases:

Cancer: Drugs such as metformin (originally for type 2 diabetes) and disulfiram (used to treat alcoholism) have shown promise in treating various cancers. Computational screening revealed that these drugs can inhibit cancer cell proliferation by targeting metabolic pathways and proteasome function, respectively.

Neurological Disorders: The repurposing of antihypertensive and anti-inflammatory drugs for conditions like Alzheimer's and Parkinson's disease has gained interest. For instance, nilotinib, a leukemia drug, has been evaluated for its ability to reduce neurotoxic proteins in Parkinson's disease.

Infectious Diseases: The urgency of the COVID-19 pandemic accelerated the search for repurposed antiviral drugs. Drugs such as remdesivir, initially developed for Ebola, and dexamethasone, a corticosteroid, were rapidly tested and approved based on evidence derived from computational screening and clinical trials.

Rare Diseases: For orphan diseases with limited treatment options, repurposing provides a lifeline. By identifying drugs already approved for other conditions, researchers can bypass lengthy development phases and offer quicker therapeutic alternatives to patients.

3.4 Challenges in Computational Drug Repurposing

Despite its promise, computational drug repurposing faces several challenges:

Data Quality and Completeness: Incomplete or noisy data can lead to inaccurate predictions. Disparities in data formats and experimental conditions also hinder meaningful integration.

Validation Requirements: Computational predictions must be validated through in vitro, in vivo, and clinical studies. This validation process is time-consuming and costly, often limiting the number of candidates that can be tested.

Biological Complexity: Diseases are multifactorial, and drug responses vary across individuals. A compound that appears promising in silico may fail due to unforeseen side effects or lack of efficacy in real-world biological systems.

Regulatory Hurdles: Even though repurposed drugs have prior approval, new indications often require additional safety and efficacy testing under regulatory frameworks. Intellectual property and market exclusivity issues can also disincentivize pharmaceutical investment.

3.5 Future Outlook

The landscape of drug discovery is undergoing a paradigm shift, with data-driven strategies taking center stage. As biological datasets continue to grow and tools for analyzing them improve, the potential for discovering novel uses for existing drugs will expand. Future directions may include:

Personalized Drug Repurposing: Integrating patient-specific genetic and phenotypic data can enable repurposing strategies tailored to individual profiles, enhancing treatment

efficacy and safety.

Real-World Data Integration: Incorporating real-world evidence from electronic health records, adverse event databases, and patient registries can refine predictions and uncover population-level drug effects.

Collaborative Platforms: Shared databases and open-access tools are fostering global collaboration in drug repurposing research. Initiatives such as DrugBank, ChEMBL, and PubChem have become invaluable resources for researchers worldwide.

Cross-Disease Analysis: As understanding of the molecular basis of diseases improves, repurposing strategies may focus on targeting shared pathways among multiple conditions, leading to broader therapeutic impact.

Computational strategies have brought significant advancements to drug repurposing and discovery by enabling efficient exploration of vast biomedical datasets. These methods help prioritize promising drug candidates, uncover hidden therapeutic opportunities, and reduce development timelines. While challenges remain, the evolving landscape of biomedical data and analytical tools offers unprecedented opportunities to transform drug discovery into a more targeted, efficient, and patient-centered process. Through continued research, validation, and collaboration, drug repurposing is poised to play a vital role in shaping the future of therapeutics across various medical disciplines.

4. AI-Enabled Mental Health Diagnosis And Monitoring

Mental health disorders are among the leading causes of disability and diminished quality of life worldwide. Conditions such as depression, anxiety, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD) affect millions of individuals, yet remain underdiagnosed and undertreated. One of the major challenges in mental health care is the reliance on subjective assessments, often based on patient self-reporting and clinical interviews. These traditional methods, while valuable, may be influenced by personal bias, recall limitations, and communication barriers. Consequently, there has been a growing interest in leveraging advanced computational methods and data-driven tools to support the diagnosis, monitoring, and management of mental health conditions. The evolution of digital health technologies ranging from smartphones and wearable devices to speech recognition and behavioral analytics has enabled the collection of a wide array of personal data. This includes voice patterns, facial expressions, typing behaviors, movement data, physiological parameters, and even social media activity. When analyzed through appropriate models, these data sources can reveal underlying emotional states, behavioral changes, and cognitive impairments indicative of mental health disorders. The integration of such tools into clinical workflows holds the potential to augment psychiatric evaluation and provide continuous, objective insights into a patient's mental state [20-24].

4.1 Limitations of Traditional Mental Health Diagnostics

Conventional psychiatric diagnosis is primarily based on criteria outlined in manuals such as the DSM (Diagnostic and Statistical Manual of Mental Disorders) or ICD (International Classification of Diseases). Clinicians use these criteria during structured interviews and observations to assess a patient's mental condition [25]. However, several challenges hinder the accuracy and timeliness of this process:

Subjectivity: Mental health symptoms are often internal and subjective. Patients may underreport or exaggerate symptoms due to stigma, fear, or misunderstanding.

Variability: Symptoms of the same disorder can vary greatly between individuals, and

some conditions share overlapping features, complicating differential diagnosis.

Limited Monitoring: Traditional diagnosis is a point-in-time assessment, lacking the ability to continuously monitor fluctuations in symptoms between clinical visits.

Delayed Intervention: Many individuals do not seek help until their condition becomes severe, by which time early intervention opportunities may have been missed.

To overcome these challenges, computational models are being employed to analyze large volumes of behavioral and physiological data in a standardized and unbiased manner, offering a more nuanced understanding of mental health.

4.2 Behavioral Signal Analysis

One of the most promising areas in digital mental health is the analysis of behavioral signals. These signals are subtle changes in how individuals interact with technology or their environment and may serve as early markers of mental health conditions.

Speech and Voice Patterns: Voice is a rich medium for detecting emotional and psychological states. Changes in pitch, tone, tempo, pause duration, and articulation can reflect mood alterations. For example, individuals with depression often speak more slowly, with reduced pitch variation and longer pauses. Conversely, those experiencing mania may exhibit rapid, pressured speech. Advanced algorithms can process these voice features to identify deviations from baseline and suggest potential mental health concerns.

Facial Expression Analysis: Facial expressions are closely tied to emotional states. Tools that track micro-expressions, eye movements, and facial muscle activity can detect signs of emotional distress. Flattened affect, lack of eye contact, and reduced facial expressiveness are common in conditions such as depression and schizophrenia. Monitoring these features over time can help in evaluating symptom severity and treatment response.

Text and Language Use: The way individuals express themselves through writing can also provide clues about their mental state. Linguistic analysis tools assess vocabulary, sentence structure, use of pronouns, emotional tone, and thematic content. For instance, excessive use of first-person singular pronouns (“I,” “me”) and negative emotion words may signal depressive thinking. Language analysis has been used to detect suicidal ideation, anxiety, and psychosis with a high degree of sensitivity.

Typing and Touch screen Behavior: Keystroke dynamics, typing speed, error rates, and touch screen interaction patterns are being investigated as digital biomarkers. Slower typing and increased errors may correlate with cognitive decline or depressive episodes, while erratic tapping behavior may indicate heightened anxiety or agitation. Such indicators are particularly valuable in mobile mental health applications, where passive data collection ensures unobtrusive monitoring.

4.3 Physiological and Environmental Monitoring

Physiological responses to stress and mood changes are also essential in mental health evaluation. With the growing availability of wearable devices, continuous monitoring of physiological signals has become feasible [26].

Heart Rate and Variability: Heart rate variability (HRV) reflects the balance between sympathetic and parasympathetic nervous system activity and is sensitive to stress, anxiety, and emotional dysregulation. A reduction in HRV is often associated with poor mental health outcomes. Wearable devices can collect HRV data during rest or activity, providing insights into the user’s stress levels and emotional resilience.

Sleep Patterns: Sleep disturbances are common in nearly all psychiatric disorders. Wearable and smartphone-based sleep tracking tools can monitor sleep onset, duration, quality, and interruptions. Deviations from normal sleep patterns can help detect early signs of relapse or treatment non-response in mood and anxiety disorders.

Physical Activity and Mobility: Reduced physical activity is a hallmark of depression, while erratic or excessive movement may be observed in mania or agitation. Location tracking and activity monitoring can provide a continuous picture of a person's behavior, helping clinicians understand whether they are isolating, overactive, or exhibiting unusual routines.

4.4 Real-Time Monitoring and Early Intervention

One of the most significant contributions of digital mental health tools is the ability to detect early signs of mental health deterioration and trigger timely intervention. Real-time monitoring systems can alert healthcare providers, caregivers, or patients themselves when abnormal patterns are detected. This allows for early check-ins, medication adjustments, or therapy sessions before symptoms escalate [27]. Such proactive care is especially important in chronic conditions like bipolar disorder or schizophrenia, where early intervention during prodromal phases can prevent full-blown episodes. Furthermore, these systems enable continuous support in between clinic visits, improving patient adherence and engagement with treatment plans.

4.5 Ethical and Privacy Considerations

While the benefits of data-driven mental health monitoring are considerable, several ethical and privacy concerns must be addressed:

Data Privacy: Sensitive personal information is being collected continuously, raising concerns about data ownership, storage, and sharing. Ensuring strict data security protocols and user consent is vital.

Informed Consent: Users must be adequately informed about what data is being collected and how it will be used. Transparency is key to building trust.

Bias and Fairness: Algorithms must be carefully designed to avoid cultural, racial, or gender bias, which could lead to inaccurate assessments or unequal treatment.

Human Oversight: Technology should augment, not replace, human judgment. Final diagnoses and treatment decisions must always involve qualified healthcare professionals.

4.6 Integration into Clinical Practice

For digital tools to be effective, they must be integrated into existing mental healthcare systems.

Training for Clinicians: Mental health professionals should be trained to interpret digital biomarkers and incorporate them into their clinical reasoning.

Interoperability: Digital systems should be compatible with electronic health records and other clinical databases to ensure seamless data exchange.

Regulatory Compliance: Tools must adhere to medical device regulations and data protection laws to be used in clinical settings.

Data-driven technologies have opened new frontiers in the diagnosis and monitoring of mental health disorders. By enabling the continuous, objective assessment of behavioral, linguistic, and physiological indicators, these tools address many limitations of traditional psychiatric evaluation. Although challenges remain regarding privacy, bias, and integration, the

potential benefits for early detection, personalized care, and improved outcomes are substantial. As the field continues to evolve, collaborative efforts between clinicians, technologists, and policymakers will be crucial to harness the full potential of these tools for enhancing mental healthcare delivery.

5. AI in Clinical Decision Support Systems (CDSS)

Clinical Decision Support Systems (CDSS) are essential components in modern healthcare environments, offering tools to assist healthcare professionals in making informed, evidence-based clinical decisions. These systems are designed to process complex medical information and provide insights that can enhance patient safety, reduce diagnostic errors, optimize treatment plans, and improve overall healthcare outcomes. As the volume of medical data continues to grow exponentially, there is a pressing need for systems that can efficiently synthesize this information and present it in a manner that supports clinical decision-making [28-30]. Historically, CDSS were based on manually coded rules, guidelines, and protocols. While these rule-based systems provided significant value in standardizing care, they often lacked adaptability, struggled to accommodate complex patient profiles, and required constant manual updates. With advancements in data analytics and computational power, more dynamic and responsive CDSS tools have emerged, capable of incorporating patient-specific data, laboratory results, clinical guidelines, and historical outcomes into real-time clinical recommendations.

This section explores the foundational principles, key functionalities, applications, challenges, and future prospects of data-driven Clinical Decision Support Systems in contemporary healthcare.

5.1 Overview of Clinical Decision Support Systems

A Clinical Decision Support System is typically integrated with electronic health record (EHR) platforms and serves as an adjunct tool that assists healthcare providers in making better decisions. CDSS tools can offer recommendations, flag potential risks, and provide alerts based on the analysis of patient data and medical knowledge bases [31]. CDSS can be broadly categorized into two types:

Knowledge-based systems: These rely on established clinical rules and logic that relate specific inputs (e.g., symptoms, lab results) to specific outputs (e.g., diagnoses, treatment options). These systems often use "if-then" rules to guide clinical decision-making.

Non-knowledge-based systems: These systems derive patterns and predictions from large datasets without relying on explicit rules. They are trained to recognize correlations in data that may be too complex for human analysis or traditional algorithms.

While knowledge-based systems are easier to interpret and audit, non-knowledge-based systems often offer greater adaptability, especially in scenarios involving heterogeneous or ambiguous data.

5.2 Functionalities of Modern CDSS

Modern Clinical Decision Support Systems are multifaceted and offer a wide range of functionalities, including:

Diagnostic Assistance: CDSS tools can analyze a patient's symptoms, history, and test results to suggest potential diagnoses. These suggestions are often accompanied by confidence scores and reference material. Diagnostic assistance is particularly useful in emergency care, radiology, pathology, and complex internal medicine cases, where timely and accurate decision-making is crucial [32].

Drug Interaction and Allergy Alerts: Medication safety is a major concern in clinical practice. CDSS can cross-reference prescribed drugs with patient allergies, existing medications, and lab results to flag potential drug-drug interactions, contraindications, or dosage errors. These alerts help prevent adverse drug events and enhance medication safety.

Treatment Recommendations: By referencing clinical guidelines and patient-specific data, CDSS can recommend treatment protocols tailored to an individual's condition, comorbidities, and preferences. For example, in managing chronic conditions such as diabetes or hypertension, CDSS tools can provide personalized medication adjustments and lifestyle modification strategies.

Laboratory and Imaging Test Suggestions: CDSS can suggest appropriate diagnostic tests based on initial clinical findings, helping to avoid unnecessary investigations and ensuring timely diagnosis. This functionality is particularly valuable in reducing the overuse of imaging studies and promoting cost-effective care.

Risk Stratification and Predictive Analytics: CDSS tools can assess a patient's risk of developing certain conditions, experiencing complications, or being readmitted after discharge. Risk prediction models can inform clinical decisions, guide preventive strategies, and optimize resource allocation.

Workflow Optimization: By automating routine tasks such as scheduling, documentation, and reminders, CDSS tools can reduce administrative burden on healthcare providers. They can also alert clinicians to critical lab values or lapses in care, such as missed screenings or vaccinations.

5.3 Applications across Medical Specialties

CDSS have found widespread application across a variety of clinical domains:

Emergency Medicine: In fast-paced emergency departments, CDSS tools assist with triage, prioritize critical cases, and support early identification of life-threatening conditions such as sepsis, stroke, or acute coronary syndrome. Rapid decision-making supported by accurate data interpretation can significantly improve patient outcomes in these settings.

Oncology: Cancer diagnosis and treatment planning involve complex decision pathways. CDSS tools can integrate genomic data, pathology reports, and clinical guidelines to support oncologists in selecting personalized treatment regimens. These systems also assist in monitoring treatment responses and adjusting therapies accordingly.

Cardiology: In cardiology, CDSS can interpret electrocardiograms (ECGs), assess risk scores for heart disease, suggest anticoagulation strategies in atrial fibrillation, and manage heart failure treatment protocols. Integration with wearable devices and remote monitoring further enhances decision-making for outpatients.

Primary Care: In primary care settings, CDSS supports preventive care by flagging due screenings, suggesting immunizations, and identifying at-risk patients based on lifestyle and demographic data. This helps in managing population health effectively.

Intensive Care Units (ICUs) : ICU environments generate vast quantities of real-time data. CDSS tools in this context help in ventilator management, fluid balance optimization, infection control, and early warning systems for patient deterioration.

5.4 Benefits of CDSS Implementation

Implementing CDSS in clinical practice offers multiple advantages:

Improved Patient Safety: By alerting clinicians to errors or omissions, CDSS can reduce

adverse events and promote evidence-based practices.

Standardization of Care: CDSS promotes adherence to clinical guidelines, reducing variations in care delivery and improving consistency.

Increased Efficiency: Automating routine decisions and documentation reduces clinician workload, allowing more time for patient interaction.

Better Resource Utilization: By guiding appropriate test ordering and treatment planning, CDSS reduces unnecessary interventions and controls costs.

5.5 Challenges and Limitations

Despite their advantages, CDSS tools face several challenges that can impact their effectiveness and acceptance:

Data Integration: Many healthcare systems still struggle with fragmented data sources and lack of interoperability between electronic health records. Effective CDSS deployment requires seamless integration of laboratory results, imaging studies, medication records, and clinical notes into a unified platform.

Alert Fatigue: Excessive alerts, especially those perceived as low priority or irrelevant, can lead to alert fatigue among clinicians. This desensitization reduces the likelihood of responding to important warnings and undermines the system's utility.

Clinical Acceptance: Some healthcare providers may be hesitant to adopt CDSS tools due to concerns about loss of autonomy, overreliance on technology, or mistrust of automated recommendations. Engaging clinicians in the design and implementation of CDSS can help address these concerns.

Customization and Scalability: CDSS tools must be tailored to the specific needs, workflows, and guidelines of different institutions. Achieving scalability while maintaining relevance and accuracy is a complex but essential goal.

Regulatory and Legal Issues: Ensuring compliance with healthcare regulations and data privacy laws is essential. Moreover, questions about liability in the case of erroneous recommendations must be addressed through clear guidelines and shared responsibility models.

5.6 Future Directions

The evolution of CDSS continues to push the boundaries of what is possible in clinical decision-making. Emerging trends and future directions include:

Context-Aware Systems: Future CDSS tools will be more context-sensitive, capable of adjusting recommendations based on the clinical environment, patient preferences, and resource availability.

Patient-Driven Decision Support: Systems that involve patients in decision-making, through portals or mobile apps, will promote shared decision-making and patient engagement.

Integration with Wearables and Remote Monitoring: Incorporating data from wearable devices and home monitoring tools will enable real-time clinical guidance for chronic disease management.

Continuous Learning Systems: Future CDSS tools may learn from past decisions and outcomes, allowing for iterative improvement in recommendations and predictions.

Clinical Decision Support Systems represent a pivotal advancement in the pursuit of safer, more effective, and personalized medical care. By providing clinicians with timely, relevant, and evidence-based recommendations, CDSS tools enhance diagnostic accuracy, reduce treatment errors, and improve patient outcomes. However, to fully realize their potential, it is essential to

address the challenges of data integration, clinician engagement, and system interoperability. With thoughtful design, regulatory support, and continuous innovation, CDSS will continue to evolve as indispensable partners in modern clinical practice.

6. Challenges and Ethical Considerations

The integration of advanced computational systems into healthcare practices particularly in areas such as drug repurposing, mental health monitoring, and clinical decision support offers numerous benefits, from improved diagnostic precision to more personalized treatment recommendations. However, alongside these advancements come significant challenges and ethical concerns that must be addressed to ensure responsible and equitable implementation. These issues span technical limitations, data quality, privacy protection, clinician-patient relationships, accountability, and regulatory compliance.

Data Quality and Accessibility: One of the foremost challenges lies in the quality, completeness, and standardization of medical data. Many healthcare datasets are fragmented across institutions, stored in different formats, or embedded in unstructured formats such as handwritten notes or clinical narratives. Incomplete or biased data can lead to unreliable outcomes, potentially causing harm when used for clinical recommendations or drug discovery. Furthermore, certain populations, such as individuals in rural areas or from underrepresented communities may be underrepresented in healthcare databases, resulting in tools that are less effective or accurate for these groups. Ensuring diverse, high-quality data is a prerequisite for reliable and equitable healthcare solutions.

Privacy and Confidentiality: Healthcare data is among the most sensitive types of personal information. Systems that analyze patient data must adhere to strict privacy standards to protect individuals from unauthorized access, data breaches, or misuse. The increasing use of mobile applications, wearables, and cloud-based platforms for collecting behavioral and physiological data raises new questions about data security. Ensuring that patients are fully informed about what data is being collected, how it will be used, and who will have access is critical. Clear data governance frameworks must be in place to enforce transparency, obtain informed consent, and safeguard against surveillance or misuse.

Algorithmic Bias and Fairness: When computational systems are trained on historical healthcare data, they may inadvertently learn and replicate existing biases present in the medical system. These biases could be related to gender, race, age, socioeconomic status, or geographic location. For example, a system trained primarily on data from one demographic group may produce inaccurate recommendations for another. Such disparities can lead to unequal access to care, misdiagnosis, or ineffective treatment. Therefore, it is essential to evaluate systems for bias during development and after deployment, and to incorporate mechanisms for ongoing monitoring and correction.

Clinical Acceptance and Trust: Healthcare professionals may be hesitant to rely on automated tools, particularly when recommendations conflict with clinical intuition or established practices. A lack of transparency in how outputs are generated can reduce trust and hinder adoption. To foster acceptance, systems must be interpretable, user-friendly, and demonstrably aligned with clinical goals. Clear documentation, clinician training, and opportunities for feedback are essential in bridging the gap between developers and healthcare providers.

Accountability and Liability: A critical ethical concern involves determining who is responsible when a computational recommendation leads to an adverse outcome. Unlike

traditional tools, advanced systems may operate in complex and opaque ways, making it difficult to trace the origin of a mistake. This raises questions about legal liability: Should responsibility fall on the clinician who acted on the recommendation, the institution that deployed the system, or the developers who designed it? Addressing these questions requires new legal and regulatory frameworks that clearly define accountability while ensuring patient safety.

Patient Autonomy and Informed Consent: Patients have a fundamental right to make informed decisions about their healthcare. When recommendations are generated through data-driven methods, there is a risk of reducing complex medical decisions to automated suggestions. This can undermine shared decision-making and patient autonomy, especially if patients feel pressured to accept recommendations without fully understanding them. Ethical implementation requires that patients be actively involved in their care and fully informed about the role of digital tools in shaping their treatment plans.

Regulatory Oversight and Standards: The pace of technological development often outstrips the ability of regulatory bodies to keep up. Many systems used in healthcare may not fall under existing definitions of medical devices or clinical tools, making their oversight ambiguous. Regulatory agencies must update guidelines to account for these new technologies, ensuring that systems are thoroughly evaluated for safety, efficacy, and equity before widespread deployment. International collaboration may also be necessary, given the global nature of technology development and healthcare delivery.

The application of advanced computational tools in healthcare offers immense promise but also introduces a range of ethical and practical challenges. Addressing these concerns requires a multidisciplinary approach involving clinicians, technologists, ethicists, policymakers, and patients. Only by establishing robust ethical guidelines, enhancing transparency, and ensuring equitable access can these innovations truly transform healthcare in a way that benefits all members of society.

7. Future Directions

The integration of advanced computational systems into healthcare has already begun reshaping the way medical professionals approach diagnosis, treatment, and patient management. As healthcare systems continue to evolve, the future holds substantial promise for enhancing drug discovery, improving mental health monitoring, and strengthening clinical decision-making. However, realizing this potential will require continued innovation, interdisciplinary collaboration, and a firm commitment to ethical, equitable implementation. The following future directions offer insights into how the landscape of healthcare may transform in the coming years.

Personalized and Precision Medicine: One of the most significant future developments lies in the transition from generalized treatment models to highly personalized approaches. By integrating genetic, biochemical, and lifestyle data with clinical histories, healthcare providers will be able to tailor therapies to individual patients more effectively. In drug repurposing, this means identifying specific patient subgroups that are most likely to benefit from an existing medication based on their genetic or molecular profile. In mental health, personalized monitoring strategies could allow clinicians to predict mood fluctuations or relapse risk before symptoms become severe. In clinical decision support, personalized recommendations will reduce trial-and-error in medication selection and improve adherence to treatment.

Real-Time, Continuous Monitoring: Advances in sensor technology, mobile devices, and wearable tools will make it possible to monitor patients continuously and in real-time, both within and outside clinical settings. This will be particularly useful in chronic disease

management and mental health care, where symptom presentation may vary widely throughout the day or week. For example, wearable devices may capture fluctuations in heart rate, sleep quality, or movement patterns, helping clinicians detect early signs of deterioration. The ability to gather and analyze longitudinal data will provide a more accurate and dynamic picture of patient health, leading to earlier interventions and better outcomes.

Integrated Health Ecosystems: Future healthcare environments will move toward fully integrated systems where patient data from various sources primary care, specialists, laboratories, pharmacies, wearable devices, and home-monitoring platforms are consolidated into unified records. This will enhance the efficiency and accuracy of clinical decision-making. In drug development, access to comprehensive population-level data may reveal unexpected correlations between treatments and outcomes, uncovering new opportunities for drug repurposing. In clinical workflows, integrated systems will reduce duplication, improve communication between care teams, and streamline care coordination.

Collaborative Decision-Making Tools: Future decision support systems will be designed not only for clinicians but also for patients and caregivers. Tools that support shared decision-making will allow patients to understand treatment options, evaluate risks and benefits, and express their preferences more clearly. Such systems will empower patients to take an active role in their healthcare, increasing satisfaction and improving treatment adherence. By creating transparent, interactive platforms, healthcare systems will foster trust and collaboration between all stakeholders involved in patient care.

Advanced Visualization and Interpretation Tools: As data becomes more complex and multidimensional, new tools will be needed to help healthcare professionals interpret results efficiently. Future systems will offer advanced visualizations such as interactive timelines, dynamic risk maps, and layered diagnostic images that help clinicians detect trends and patterns not easily seen through standard charts or tables. These enhancements will support faster decision-making and reduce the likelihood of oversight in complex cases.

Expanded Role in Public Health and Policy: Beyond individual care, computational tools will play an increasingly important role in shaping public health strategies. By analyzing trends in disease incidence, treatment efficacy, and healthcare access, these tools can help governments and organizations develop more targeted interventions and allocate resources effectively. During public health emergencies, rapid identification of existing drugs with potential utility—based on real-world data can aid in emergency response planning and therapeutic development.

Global Collaboration and Open Science: The future of medical innovation will depend heavily on collaboration across institutions, disciplines, and nations. Open data initiatives, shared repositories, and cooperative research networks will accelerate progress by reducing redundancy and promoting transparency. In the context of drug repurposing, global databases containing chemical, genomic, and clinical information will allow researchers to identify candidate compounds more efficiently. In mental health, shared tools and assessment frameworks can promote early detection and intervention across diverse populations.

Ethical, Transparent, and Inclusive Implementation: Looking ahead, healthcare systems must prioritize the development of ethically sound and socially inclusive technologies. This includes ensuring that all populations regardless of age, gender, race, income, or geographic location benefit equally from advances in computational medicine. Tools should be designed with fairness, privacy, and accessibility in mind. Policymakers and regulatory agencies must also adapt to evolving technologies by creating frameworks that support innovation while protecting

patient rights and safety.

The future of modern healthcare is poised to become more connected, predictive, and patient-centered. Continued advancements in computational capabilities will enhance the ability to discover new drug applications, monitor mental health in real-time, and support clinicians in making complex medical decisions. To fully harness these possibilities, a concerted effort is needed to address current challenges, bridge gaps between research and clinical application, and foster inclusive, ethical development. As these systems mature, they will play an increasingly vital role in delivering safer, more effective, and more responsive care for individuals and populations alike.

8. Conclusion

The integration of advanced computational tools in healthcare has opened new avenues for improving patient outcomes, streamlining clinical workflows, and accelerating the development of effective treatments. This review has examined three critical domains where such tools are making a significant impact: drug repurposing, mental health monitoring, and clinical decision support systems. In drug repurposing, analytical techniques have facilitated the identification of new therapeutic uses for existing compounds, offering a faster and more cost-effective path to treatment. In mental health, digital monitoring systems provide timely, objective insights that enhance diagnosis and enable continuous care. Clinical decision support tools, when effectively implemented, assist healthcare professionals in making accurate, evidence-based decisions, ultimately improving safety and efficiency. While challenges such as data quality, privacy, and ethical concerns remain, ongoing research, collaboration, and thoughtful regulation can help overcome these barriers. As technology continues to evolve, its responsible application in healthcare will play a central role in shaping the future of medical practice.

Acknowledgment: Not Applicable.

Funding Statement: The author(s) received no specific funding for this study.

Conflicts of Interest: The authors declare no conflicts of interest to report regarding the present study

References

- [1] S. Iyanna, P.Kaur, P. Ractham, S. Talwar and A.N. Islam, "Digital transformation of healthcare sector. What is impeding adoption and continued usage of technology-driven innovations by end-users?," *Journal of Business Research*, vol.153, pp.150-161, 2022.
- [2] M. Rudrapal, S.J. Khairnar and A.G. Jadhav, "Drug repurposing (DR): An emerging approach in drug. Drug repurposing: Hypothesis, molecular aspects and therapeutic applications," *Hamburg, Germany: Books on Demand*, pp.3-22, 2020.
- [3] S. Quazi, "Artificial intelligence and machine learning in precision and genomic medicine," *Medical Oncology*, vol.39, no.8, pp.120, 2022.
- [4] A. Fakih, "The Effect of Clinical Decision Support Tools on Physicians' Practices," *The Journal of the Association of Physicians of India*, vol.73, no.2, pp.26-30, 2025.
- [5] K.K. Vaigandla, "A Systematic Survey on Artificial Intelligence in 6G Wireless Networks: Security, Opportunities, Applications, Advantages, Future Research Directions and Challenges," *Babylonian Journal of Artificial Intelligence*, vol.2025, pp.99-106, 2025.
- [6] P. Hamet and J. Tremblay, "Artificial intelligence in medicine," *Metabolism*, vol.69, pp.S36-S40, 2017.

-
- [7] K.K. Vaigandla, R. Karne, M.K. Vanteru, M. Devsingh, D. Prasad, R.K. Siddoju and N. Dharavath, "Artificial Intelligence in Industrial IoT: Trends, Challenges, and Future Directions," *Journal of Computer Allied Intelligence*, vol.3, no.2, pp.37-55, 2025.
- [8] H. Sheikh, C. Prins and E. Schrijvers, "Artificial intelligence: definition and background," *In Mission AI: The new system technology*, pp. 15-41, 2023.
- [9] V. Yashchenko, "Artificial intelligence theory (Basic concepts)," *In 2014 Science and Information Conference*, pp. 473-480, 2014.
- [10] A. Valavanidis, "Artificial intelligence (ai) applications," *Department of Chemistry, National and Kapodistrian University of Athens, University Campus Zografou*, vol.15784, 2023.
- [11] Y. Lu, "Artificial intelligence: a survey on evolution, models, applications and future trends," *Journal of management analytics*, vol.6, no.1, pp.1-29, 2019.
- [12] I. Celik, M. Dindar, H. Muukkonen and S. Järvelä, "The promises and challenges of artificial intelligence for teachers: A systematic review of research," *Tech Trends*, vol.66, no.4, pp.616-630, 2022.
- [13] S. Mohanty, M.H.A. Rashid, M. Mridul, C. Mohanty and S. Swayamsiddha, "Application of Artificial Intelligence in COVID-19 drug repurposing," *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, vol.14, no.5, pp.1027-1031, 2022.
- [14] S. Quazi, "Role of artificial intelligence and machine learning in bioinformatics: Drug discovery and drug repurposing," *The Lancet Digital Health*, 2021.
- [15] Y. Zhou, F. Wang, J. Tang, R. Nussinov and F. Cheng, "Artificial intelligence in COVID-19 drug repurposing," *The Lancet Digital Health*, vol.2, no.12, pp.e667-e676, 2020.
- [16] H. Farghali, N.K. Canová and M. Arora, "The potential applications of artificial intelligence in drug discovery and development," *Physiological Research*, vol.70, no.Suppl 4, pp.S715, 2021.
- [17] M. Aljofan and A. Gaipov, "Drug discovery and development: the role of artificial intelligence in drug repurposing," *Future Medicinal Chemistry*, vol.16, no.7, pp.583-585, 2024.
- [18] X. Li, J.F. Rousseau, Y. Ding, M. Song and W. Lu, "Understanding drug repurposing from the perspective of biomedical entities and their evolution: Bibliographic research using aspirin," *JMIR medical informatics*, vol.8, no.6, pp.e16739, 2020.
- [19] K. Park, "A review of computational drug repurposing," *Translational and clinical pharmacology*, vol.27, no.2, pp.59, 2019.
- [20] Y. Ni and F. Jia, "A scoping review of AI-Driven digital interventions in mental health care: mapping applications across screening, support, monitoring, prevention, and clinical education," *In Healthcare*, vol. 13, no. 10, pp. 1205, 2025.
- [21] R. Ajayi, "AI-powered innovations for managing complex mental health conditions and addiction treatments," *International Research Journal of Modernization in Engineering Technology and Science*, pp.1-18, 2025.
- [22] T. Shaik, X. Tao, N. Higgins, H. Xie, R. Gururajan and X. Zhou, "AI enabled RPM for mental health facility," *In Proceedings of the 1st ACM Workshop on Mobile and Wireless Sensing for Smart Healthcare*, pp. 26-32, 2022.
-

-
- [23] E.A. Paraschiv, L. Băjenaru, C. Petrache, O. Bica and D.N. Nicolau, "AI-driven neuro-monitoring: advancing schizophrenia detection and management through deep learning and EEG analysis," *Future Internet*, vol.16, no.11, pp.424, 2024.
- [24] D. Karimzadeh and A. Saeedi, "AI for Mental Health Assessment and Intervention: A Systematic Review," *International journal of Modern Achievement in Science, Engineering and Technology*, vol.2, no.1, pp.96-104, 2024.
- [25] D.A. Regier, C.T. Kaelber, D.S. Rae, M.E. Farmer, B. Knauper, R.C. Kessler and G.S. Norquist, "Limitations of diagnostic criteria and assessment instruments for mental disorders: implications for research and policy," *Archives of general psychiatry*, vol.55, no.2, pp.109-115, 1998.
- [26] R.D. Handy and M.H. Depledge, "Physiological responses: their measurement and use as environmental biomarkers in ecotoxicology," *Ecotoxicology*, vol.8, no.5, pp.329-349, 1999.
- [27] S. Basheer, A.S. Alluhaidan and M.A. Bivi, "Real-time monitoring system for early prediction of heart disease using Internet of Things," *Soft Computing*, vol.25, no.18, pp.12145-12158, 2021.
- [28] M. Elhaddad and S. Hamam, "AI-driven clinical decision support systems: an ongoing pursuit of potential," *Cureus*, vol.16, no.4, 2024.
- [29] L. Wang, X. Chen, L. Zhang, L. Li, Y. Huang, Y. Sun and X. Yuan, "Artificial intelligence in clinical decision support systems for oncology," *International Journal of Medical Sciences*, vol.20, no.1, pp.79, 2023.
- [30] W.C. Juang, M.H. Hsu, Z.X. Cai and C.M. Chen, "Developing an AI-assisted clinical decision support system to enhance in-patient holistic health care," *Plos one*, vol.17, no.10, pp.e0276501, 2022.
- [31] E.S. Berner and T.J. La Lande, "Overview of clinical decision support systems," *In Clinical decision support systems: Theory and practice*, pp. 1-17, 2016.
- [32] J.D. Mujumdar and H. Jeffcoat, "How Clinical Decision Support Tools Can Be Used to Support Modern Care Delivery," *facs. org/clincon*, vol.2022, no.20, 2022.